Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Non-Current Assets (2024 - 2026)

Maze Therapeutics' Non-Current Assets history spans 3 years, with the latest figure at $39.9 million for Q1 2026.

  • On a quarterly basis, Non-Current Assets rose 20.52% to $39.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $150.5 million, a N/A change, with the full-year FY2025 number at $47.4 million, up 21.97% from a year prior.
  • Non-Current Assets hit $39.9 million in Q1 2026 for Maze Therapeutics, down from $47.4 million in the prior quarter.
  • Over the last five years, Non-Current Assets for MAZE hit a ceiling of $47.4 million in Q4 2025 and a floor of $30.8 million in Q3 2025.
  • Historically, Non-Current Assets has averaged $37.1 million across 3 years, with a median of $36.0 million in 2024.
  • Biggest five-year swings in Non-Current Assets: grew 21.97% in 2025 and later grew 20.52% in 2026.
  • Tracing MAZE's Non-Current Assets over 3 years: stood at $38.9 million in 2024, then rose by 21.97% to $47.4 million in 2025, then dropped by 15.78% to $39.9 million in 2026.
  • Business Quant data shows Non-Current Assets for MAZE at $39.9 million in Q1 2026, $47.4 million in Q4 2025, and $30.8 million in Q3 2025.